Peptide record

TPDB05643

[RW]4 Antibacterial Anticancer Antifungal Antiviral Cell-penetrating Peptides Toxicity standard
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05643
[RW]4
Antibacterial Anticancer Antifungal Antiviral Cell-penetrating Peptides Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 Peptipedia CancerPPD 2.0 SATPdb dbACP CAFPdb DRAMP dbAMP CellPPD-MOD CPPsite3.0 PerseuCPP
standard
No
A 8-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
RWRWRWRW
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C68H90N24O9
ANDCEQGHILKMFPSTYV
RW
1387.62
12.88
4
0
4
+4
6.30
-2.700
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
22000
15.85
0
Residue Composition
number
0
A
4
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
4
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 4 Y: 0 V: 0
Chemical Descriptors
8 reviewed residue count
C68H90N24O9 sequence-only estimate (linear, free termini)
1387.62 sequence-only estimate (linear, free termini)
12.88 sequence-only estimate (linear, free termini)
+4 sequence-only estimate (linear, free termini)
6.30 sequence-only estimate (linear, free termini)
-2.700 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Cationic Activity
Cyclic Activity
Free Activity
N[C@@H](CS)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O Activity
Evidence Records 5 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

MCF-7

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Cyclic L Cationic
Synthetic
Silver nanoparticles (AgNPs)
Mitochondria
Enhance uptake of AgNP
Phagocytosis or passive nonspecific diffusion
In vitro
CCCCSSTTSCCC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

A549 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Cyclic L Cationic
Synthetic
Quantum dots (QDs)
Nucleus
Less uptake than R9 and R5W3R4
In vitro
CTTTHHHHHHHTTC
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
50% Hemolysis | 100 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Length effects in antimicrobial peptides of the (RW)n series | Antimicrob Agents Chemother | 2007
Evidence 4 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Proline-Modified RWn Peptides: Enhanced Antifungal Efficacy and Synergy with Conventional Antibiotics for Combating Resistant Fungal Infections | ACS Omega | 2024
Evidence 5 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Proline-Modified RWn Peptides: Enhanced Antifungal Efficacy and Synergy with Conventional Antibiotics for Combating Resistant Fungal Infections | ACS Omega | 2024
Additional Detail Fields 1 fields
CCCCSSTTSCCC CTTTHHHHHHHTTC